Clarivate Epidemiology's coverage of myasthenia gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of myasthenia gravis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology's myasthenia gravis forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of myasthenia gravis and the number of new diagnoses of myasthenia gravis?
In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of myasthenia gravis and the number of new diagnoses of myasthenia gravis?
How will improvements in survival change the number of people living with a diagnosis of myasthenia gravis?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of myasthenia gravis over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology also provides at least ten years of forecast data for the following myasthenia gravis subpopulations:
Diagnosed prevalent cases by disease subtype.
Diagnosed prevalent cases of Myasthenia gravis with Anti-AchR Seropositive.
Diagnosed prevalent cases of Myasthenia gravis with Thymoma.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.